After studying this material, you should be able to:
A Polygenic Risk Score (PRS) is a numerical estimate of an individual's genetic predisposition to a disease or trait, calculated by combining the effects of hundreds to millions of genetic variants (typically single nucleotide polymorphisms, or SNPs).
Individual's DNA
↓
Identify relevant genetic variants (SNPs)
↓
Weight each variant by its effect size
↓
Sum all weighted variants
↓
= Polygenic Risk Score (PRS)
For BMI prediction, your PRS might combine 500,000 genetic variants, each contributing a tiny effect, to estimate your genetic tendency toward higher or lower body weight.
Historically, genome-wide association studies (GWASs) — the research that identifies which genetic variants matter — have been conducted almost exclusively in European populations.
Historical GWAS Data
├── ~80% European populations
├── ~10% Asian populations
└── ~10% All other populations combined
| Reason | Explanation | Simple Analogy |
|---|---|---|
| Different genetic architectures | Different variants cause the same trait in different populations | Different roads leading to the same destination |
| Population structure | Genetic relatedness patterns differ between groups | Different family trees |
| Allele frequency differences | Variants are more/less common across populations | Words that exist in one language but not another |
Conducting new, large-scale GWASs from scratch (de novo) across hundreds of thousands of individuals is cost-prohibitive for most healthcare systems.
This creates the central challenge: How do we improve PRS accuracy for underrepresented populations without always starting from scratch?
Transfer learning means taking knowledge learned from one domain and applying it to a related but different domain.
Transfer Learning in Genomics:
Large European GWAS (source)
↓
Transfer knowledge
↓
Small Target Population GWAS (target)
↓
Combined, improved PRS
This research tested transfer learning between two major biobanks:
| Biobank | Population | Size |
|---|---|---|
| UK Biobank (UKB) | European | Hundreds of thousands |
| Biobank Japan (BBJ) | Japanese | ~200,000 individuals |
Eight traits studied:
Performance measured using: Pearson correlation between predicted and actual trait values
⚠️ Key Insight: Adding European data helps when Japanese sample sizes are small, but actively hurts prediction accuracy once Japanese samples grow large enough.
PRS Performance in Japanese Population
High | ╭──── Japanese-only model
| ╱
| ╱ ← Crossover (~15,000 samples)
| ╱╲
| ╱ ╲____ Combined model (European + Japanese)
Low |___╱
0 5k 15k 25k 50k 100k
Japanese Sample Size
| Japanese Sample Size | Best Strategy |
|---|---|
| < 5,000 samples | Use European data — provides valuable statistical boost |
| ~15,000 samples | Crossover point — roughly equivalent |
| > 15,000 samples | Japanese-only data outperforms combined approach |
When European data is included in training:
Genetic correlation measures how similar the genetic basis of a trait is across two populations.
Genetic Correlation Scale:
0.0 ────────────────────── 1.0
Completely Identical genetic
different architecture
(population- (conserved trait)
specific)
(e.g., BMI, blood pressure, blood cell counts)
Conserved Trait (e.g., BMI):
Performance
│ ╭── Japanese-only
│ ╱
│ ╱ ← Crossover at ~40k
│ ╭────────────╱
│ ╱ Combined model stays competitive longer
└──────────────────────────
5k 15k 25k 40k 100k
(e.g., HDL cholesterol, LDL cholesterol, blood glucose)
Population-Specific Trait (e.g., HDL):
Performance
│ ╭── Japanese-only
│ ╱
│ ╱ ← Early crossover (~15k)
│ ╭───╱
│ ╱ Combined model degrades faster
└──────────────────────────
5k 15k 25k 40k 100k
| Trait Type | Example Traits | Crossover Point | Why |
|---|---|---|---|
| Conserved | BMI, blood pressure | 25,000–40,000+ samples | Shared genetic architecture |
| Population-specific | HDL, LDL, blood glucose | ~15,000 samples | Unique genetic variants per population |
UKB European GWAS ──┐
├── Meta-Analysis → Expanded Variants → Elastic Net
BBJ Japanese GWAS ──┘
Best for: Population-specific traits (HDL, LDL, blood glucose) at moderate sample sizes
| Sample Size | Best Strategy |
|---|---|
| < 10,000 BBJ samples | European discovery + Elastic Net |
| 10,000–25,000 BBJ samples | Meta-analysis (especially for population-specific traits) |
| > 25,000 BBJ samples | PRS-CSx begins to compete |
| ~100,000 BBJ samples | PRS-CSx matches or exceeds all others (except blood glucose) |
Performance Over Time:
High │ ╭── PRS-CSx
│ ╭──────────────╯
│ ╭─────────╯ Meta-analysis
│────╯ European-only
Low └────────────────────────────────
5k 25k 50k 75k 100k
BBJ Sample Size
START: What is your target population sample size?
│
┌─────────┴──────────┐
│ │
< 15,000 > 15,000
│ │
Use European Is the trait conserved
data pooling or population-specific?
│
┌──────────┴──────────┐
│ │
Conserved Population-specific
│ │
Continue pooling Stop pooling European
European data up data; use meta-analysis
to 40k samples or Japanese-only model
| Factor | Question to Ask | Impact |
|---|---|---|
| Sample size | How many target population samples do I have? | Determines if transfer learning helps |
| Trait type | Is the genetic architecture shared across populations? | Sets the crossover threshold |
| Available resources | Can I run population-specific GWAS? | Determines which methods are feasible |
Bigger isn't always better — blindly adding out-of-population data can harm predictions
Know your trait — genetic correlation between populations should guide your modeling strategy
Method selection matters — simple elastic net models can outperform sophisticated methods like PRS-CSx at smaller sample sizes
Diverse biobanks are essential — no amount of transfer learning fully compensates for lack of target-population data
Current State Ideal Future State
───────────────── ──────────────────
European-dominated GWAS → Diverse, global biobanks
One-size-fits-all PRS → Population-tailored models
Transfer learning as fix → Transfer learning as supplement
| Concept | Core Message |
|---|---|
| PRS cross-population failure | European-trained PRSs perform poorly in non-European populations due to genetic architecture differences |
| Transfer learning benefit | Helps when target population data is scarce (< 15,000 samples) |
| Transfer learning harm | Degrades accuracy as target population grows, especially for population-specific traits |
| Conserved traits | Benefit from European data longer (up to 40,000+ samples) |
| Population-specific traits | Benefit from European data only at very small sizes |
| Meta-analysis | Best intermediate strategy for population-specific traits |
| PRS-CSx | Most powerful at large sample sizes (> 25,000–100,000) |
| Core recommendation | Match your modeling strategy to both your sample size AND your trait's genetic architecture |